<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044277</url>
  </required_header>
  <id_info>
    <org_study_id>PSHCI 09-059</org_study_id>
    <nct_id>NCT01044277</nct_id>
  </id_info>
  <brief_title>Oral Glutathione Supplementation on the Levels of Blood Glutathione</brief_title>
  <official_title>Effect of Oral Glutathione Supplementation on the Levels of Blood Glutathione and Markers of Oxidative Stress in Healthy Adults (Glutathione Supplementation and Health (GSH) Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to provide evidence of the efficacy of glutathione supplementation and&#xD;
      health(GSH) and includes the assessment of both short term and long term effects. Based on&#xD;
      previous laboratory animal studies and clinical data, the investigators anticipate that the&#xD;
      effects of oral GSH supplementation will be progressive and cumulative. The study will also&#xD;
      allow for the evaluation of effects of withdrawal of the supplement on the outcome variables.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind, placebo-controlled study in which the treatment&#xD;
      allocations will be kept sealed until the final statistical evaluation. The design will&#xD;
      include the recruitment of 60 healthy subjects (30-79 yr of age) randomized into 3 groups. A&#xD;
      total of 48 subjects, 16 per group will be required based upon power calculations and results&#xD;
      from a previous clinical trial with selenium. An additional 4 subjects per group will be&#xD;
      placed on trial to account for possible attrition or non-compliance. Blood, urine and&#xD;
      exfoliated buccal mucosal samples will be obtained from all subjects at baseline.&#xD;
      Questionnaire data on usual dietary intake will also be obtained at baseline. Eligible&#xD;
      subjects will be required to have not have taken any high dose antioxidant supplements for at&#xD;
      least 1 month prior to the study. Subjects will then begin supplementation according to the&#xD;
      following schedule:&#xD;
&#xD;
      Group A, GSH (500 mg, 2 times daily); Group B, GSH (125 mg, 2 times daily); Group C, placebo&#xD;
      (2 times daily). Eligible participants who sign the informed consent will be randomly&#xD;
      assigned to either placebo or high or low dose Glutathione groups. Participants will be asked&#xD;
      not to consume any other high-dose vitamin, multi-vitamin, or mineral supplements containing&#xD;
      glutathione throughout the study in order to prevent variation in dose of supplemental GSH&#xD;
      between subjects. Supplementation will continue for 6 months with biological samples&#xD;
      collected at 1, 3 and 6 months after baseline. At 6 months, supplementation will be&#xD;
      discontinued. A final collection of biological samples will occur 1 month afterwards.&#xD;
      Compliance will be monitored by pill count.&#xD;
&#xD;
      Levels of glutathione will be measured in plasma, lymphocytes, and red blood cells as well as&#xD;
      in exfoliated buccal mucosal cells. Biomarkers of oxidative stress will include blood levels&#xD;
      of glutathionylated proteins and 8-isoprostanes and urine levels of 8-hydroxydeoxyguanosine.&#xD;
      Glutamylcystine ligase and GST activities, and C-reactive protein will be determined in&#xD;
      blood. Immune function biomarkers will be analyzed including t-natural killer cell&#xD;
      cytotoxicity, lymphoproliferation, neutrophils phagocytosis, neutrophil respiratory burst&#xD;
      assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drugs unavailable&#xD;
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind - GSH 500 mg/GSH 125 mg/Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effect of glutathione on key biomarkers</measure>
    <time_frame>6 to 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluations will be carried out to expand the above comparison by including adjustments for potential prognostic factors.</measure>
    <time_frame>6 to 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo&#xD;
Other name Gluthathione peroxidases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo&#xD;
Other name Gluthathione peroxidases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutathione supplementation</intervention_name>
    <description>500 mg, two times daily</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Gluthathione Peroxidates</other_name>
    <other_name>GSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gluthathione peroxidases</intervention_name>
    <description>125 mg, two times daily</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Glutathione supplementation</other_name>
    <other_name>GSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 times daily</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Gluthathione peroxidases</other_name>
    <other_name>GSH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and females between the ages of 30 and 79 years of age&#xD;
&#xD;
          -  Not taking glutathione as a dietary supplement&#xD;
&#xD;
          -  Not taking high dose antioxidant supplement prior to 1 month&#xD;
&#xD;
          -  Baseline blood glutathione level of &lt; 1 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence of disease including cancer, diabetes, heart disease&#xD;
&#xD;
          -  Subjects who smoke&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Richie, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>John P. Richie</investigator_full_name>
    <investigator_title>Professor of Public Health Sciences and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>glutathione</keyword>
  <keyword>gluthathione peroxidases</keyword>
  <keyword>GSH</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>At this time we have no plan for sharing, however, if the need should arise, then sharing may be a possibility.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

